Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Simms

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Arthritis Care & Research|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
The Journal of Rheumatology|May 17, 2011
Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysisRoozbeh Sharif, Marvin J Fritzler, Maureen D Mayes, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
The Journal of Investigative Dermatology|November 29, 2017
Antisense Long Non-Coding RNAs Are Deregulated in Skin Tissue of Patients with Systemic SclerosisTobias C Messemaker, Loubna Chadli, Guoshuai Cai, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2023
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic SclerosisRobert Spiera, Masataka Kuwana, Dinesh Khanna, et al.
The Lancet. Rheumatology|December 30, 2021
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trialLorinda Chung, Cathie Spino, Richard McLain, et al.
Plos One|January 3, 2018
Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populationsOlga Y Gorlova, Yafang Li, Ivan Gorlov, et al.
Seminars in Arthritis and Rheumatism|January 13, 2015
Antinuclear antibody-negative systemic sclerosisGloria A Salazar, Shervin Assassi, Fredrick Wigley, et al.
ACR Open Rheumatology|November 26, 2025
Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis-Related Interstitial Lung Disease (Scleroderma Lung Study III): An Investigator-Initiated, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 TrialDinesh Khanna, Cathie Spino, Donald P Tashkin, et al.
Arthritis Research & Therapy|January 22, 2016
Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patientsMinghua Wu, Shervin Assassi, Gloria A Salazar, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Arthritis Care & Research|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
The Journal of Rheumatology|May 17, 2011
Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysisRoozbeh Sharif, Marvin J Fritzler, Maureen D Mayes, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
The Journal of Investigative Dermatology|November 29, 2017
Antisense Long Non-Coding RNAs Are Deregulated in Skin Tissue of Patients with Systemic SclerosisTobias C Messemaker, Loubna Chadli, Guoshuai Cai, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2023
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic SclerosisRobert Spiera, Masataka Kuwana, Dinesh Khanna, et al.
The Lancet. Rheumatology|December 30, 2021
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trialLorinda Chung, Cathie Spino, Richard McLain, et al.
Plos One|January 3, 2018
Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populationsOlga Y Gorlova, Yafang Li, Ivan Gorlov, et al.
Seminars in Arthritis and Rheumatism|January 13, 2015
Antinuclear antibody-negative systemic sclerosisGloria A Salazar, Shervin Assassi, Fredrick Wigley, et al.
ACR Open Rheumatology|November 26, 2025
Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis-Related Interstitial Lung Disease (Scleroderma Lung Study III): An Investigator-Initiated, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 TrialDinesh Khanna, Cathie Spino, Donald P Tashkin, et al.
Arthritis Research & Therapy|January 22, 2016
Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patientsMinghua Wu, Shervin Assassi, Gloria A Salazar, et al.
Pageof 8